Literature DB >> 12847693

Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease.

Sanjay Rajagopalan1, Dana Pfenninger, Christine Kehrer, Anjan Chakrabarti, Emily Somers, Robert Pavlic, Debabrata Mukherjee, Robert Brook, Louis G D'Alecy, Mariana J Kaplan.   

Abstract

OBJECTIVE: To compare microvascular and macrovascular functions in a cohort of patients with primary and secondary Raynaud's phenomenon (RP) who were matched for demographic, risk factor, and severity profiles.
METHODS: Forty patients with primary or secondary RP matched for vascular risk factors and severity scores underwent testing of endothelial function and cold pressor responsiveness of the brachial artery. Microvascular perfusion of the digital vasculature was assessed using laser Doppler fluxmetry in response to reactive hyperemia. Plasma was assayed for endothelin 1 (ET-1), asymmetric dimethylarginine (ADMA), intercellular adhesion molecule 1, vascular cell adhesion molecule 1 (VCAM-1), and monocyte chemoattractant protein 1 (MCP-1).
RESULTS: Patients with RP had abnormal vasoconstrictor responses to cold pressor tests (CPT) that were similar in primary and secondary RP. There were no differences in median flow-mediated and nitroglycerin-mediated dilation or CPT of the brachial artery in the 2 populations. Patients with secondary RP were characterized by abnormalities in microvascular responses to reactive hyperemia, with a reduction in area under the curve adjusted for baseline perfusion, but not in time to peak response or peak perfusion ratio. Plasma ET-1, ADMA, VCAM-1, and MCP-1 levels were significantly elevated in secondary RP compared with primary RP. There was a significant negative correlation between ET-1 and ADMA values and measures of microvascular perfusion but not macrovascular endothelial function.
CONCLUSION: Secondary RP is characterized by elevations in plasma ET-1 and ADMA levels that may contribute to alterations in cutaneous microvascular function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847693     DOI: 10.1002/art.11060

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

Review 1.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

Review 2.  New lines in therapy of Raynaud's phenomenon.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

3.  Raynaud's phenomenon and vitamin D.

Authors:  Josiane Hélou; Roy Moutran; Ismael Maatouk; Fady Haddad
Journal:  Rheumatol Int       Date:  2012-05-12       Impact factor: 2.631

4.  Nailfold capillaroscopy assessment of microcirculation abnormalities and endothelial dysfunction in children with primary or secondary Raynaud syndrome.

Authors:  Joanna Latuskiewicz-Potemska; Antonina Chmura-Skirlinska; Ryszard J Gurbiel; Elzbieta Smolewska
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

5.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

Review 6.  The association between systemic sclerosis, arginine and asymmetric dimethylarginine.

Authors:  Li Zhang; Ya-Nan Wan; Jiu-Hua Zhao; Yu-Jie Wang; Ying-Xin Wang; Jun-Wei Yan; Xiao-Lei Huang; Jing Wang
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 7.  Complementary therapies for patients with systemic sclerosis.

Authors:  Kimberly Showalter; Aileen Hoffmann; Nicole DeCredico; Anjali Thakrar; Esperanza Arroyo; Isaac Goldberg; Monique Hinchcliff
Journal:  J Scleroderma Relat Disord       Date:  2019-03-29

Review 8.  Recent achievements in the management of Raynaud's phenomenon.

Authors:  Magnus Baumhäkel; Michael Böhm
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

9.  Discrepancy between simultaneous digital skin microvascular and brachial artery macrovascular post-occlusive hyperemia in systemic sclerosis.

Authors:  Matthieu Roustit; Grant H Simmons; Jean-Philippe Baguet; Patrick Carpentier; Jean-Luc Cracowski
Journal:  J Rheumatol       Date:  2008-06-15       Impact factor: 4.666

10.  The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension.

Authors:  D Mukerjee; L B Yap; V Ong; C P Denton; K Howells; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.